Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 in second-line recurrent or metastatic cervical cancer
NL-OMON61155Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in Cervical Cancer (CC), sponsored by Merck & Co.. Started Sep 2024; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON61155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61155.